Senaste nyheterna

22 September 2022 14:06

Otsuka kondigt aan dat de EC Lupkynis®▼ (voclosporine) heeft goedgekeurd als eerste orale behandeling voor actieve lupus nefritis

LONDEN, VK, 20 september 2022 – Otsuka Pharmaceutical Europe Co. Ltd. heeft vandaag aangekondigd dat de Europese Commissie (EC) Lupkynis® (voclosporine) in combinatie met mycofenolaatmofetil heeft goedgekeurd voor de behandeling van volwassen patiënten met actieve klasse III, IV of V (inclusief gemengde klasse III/V en IV/V) lupus nefritis (LN). Het besluit van de Europese Commissie geldt voor all

20 September 2022 15:43

Otsuka tillkännager EU-kommissionens godkännande av Lupkynis®▼ (voklosporin) som första orala behandling för aktiv lupus nefrit

LONDON, STORBRITANNIEN, 20 september 2022 – Otsuka Pharmaceutical Europe Ltd. tillkännager idag att EU-kommissionen har godkänt Lupkynis® (voklosporin) i kombination med mykofenolatmofetil (MMF) för behandling av vuxna patienter med aktiv klass III, IV eller V (däribland blandad klass III/V och IV/V) lupus nefrit (LN). EU-kommissionens beslut gäller alla 27 medlemsländer inom EU samt Island, Norge

20 September 2022 15:35

Otsuka tillkännager EU-kommissionens godkännande av Lupkynis®▼ (voklosporin) som första orala behandling för aktiv lupus nefrit

Kontakter

Teresia Nilsson

Presskontakt Managing Director info@otsuka.se 08-545 286 60

Madeleine Rockler

Presskontakt Communications Coordinator madeleine.rockler@otsuka.se 08-545 286 60

Carina Eklöw

Presskontakt Medical Director info@otsuka.se 08-545 286 60

Otsuka Pharma Scandinavia AB

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, focusing on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs in several under-addressed diseases including tuberculosis, a significant global public health issue.

Otsuka Europe employs approximately 500 people and focuses on psychiatric and neurologic disorders, infectious disease, nephrology, oncology, and digital medicines. Otsuka Pharmaceutical Europe Ltd. is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan.

The Otsuka group of companies employed 47,000 people worldwide and a spend of €1.8 billion on research and development in 2020. For further information on Otsuka, please visit www.otsuka.se